2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 3038

Serum CXCL8, 10 and 12 Are Increased in Patients with Behcet’s Disease and CXCL10 Levels Are Correlated with Number of Erythema Nodosum
Abstract Number: 222

Serum Delta Neutrophil Index Measurement for Differentiating Acute Gouty Arthritis and Cellulitis in Normouricemic Patients
Abstract Number: 1847

Serum Ferritin and Insulin-like Growth Factor-Binding Protein 2 As Biomarkers of Clinical and Histopathological Treatment Response in Lupus Nephritis
Abstract Number: 1527

Serum Inflammation Identifies Increased Risk of Frailty in Rheumatoid Arthritis
Abstract Number: 329

Serum Leptin and Risk of Knee Pain and Osteoarthritis: Multicenter Osteoarthritis Study
Abstract Number: 753

Serum Levels of Tenascin-C Discriminate Patients with Active SLE from Inactive Patients and Healthy Controls, and Predict the Need to Escalate Immunosuppressive Therapy
Abstract Number: 2606

Serum Myeloid Related Protein 8/14 Levels in Rheumatoid Arthritis: Marker of Disease Activity and Response to Methotrexate in DMARD Naïve Patients
Abstract Number: 1509

Serum Nitrite Levels in Rheumatoid Arthritis and Relationship to Cardiovascular Risk Factors and Atherosclerosis Biomarkers
Abstract Number: 607

Serum Progranulin (PRGN) Level Is Not a Biomarker for Responsiveness to Tumor Necrosis Factor (TNF)-Antagonist Therapy in Rheumatoid Arthritis (RA) Patients
Abstract Number: 2622

Serum RANKL Levels, Associate with Anti Citrullinated Proteins Antibodies (ACPA) in Early-Untreated Rheumatoid Arthritis and Is Modulated Following Methotrexate
Abstract Number: 1578

Serum Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Antibody Are Associated with Subclinical Interstitial Lung Disease in the Multi-Ethnic Study of Atherosclerosis: A Population-Based Study
Abstract Number: 1669

Serum Survivin Predicts Responses to Treatment in Active Rheumatoid Arthritis
Abstract Number: 1858

Serum Tartrate Resistant Acid Phosphatase (TRAP) Levels Are Decreased and Associated with Anti-Maa Antibodies in Systemic Lupus Erythematosus (SLE) Patients
Abstract Number: 230

Serum Uric Acid As Short Term Mortality Predictor in the Acute Care Setting
Abstract Number: 121

Serum Uric Acid Levels and Gout Flares in a US Managed Care Setting

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].